Gene clues may predict lung function in rare disease

NCT ID NCT04901715

Completed Knowledge-focused Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how well people with Primary Ciliary Dyskinesia (PCD) clear mucus from their lungs, based on which gene mutation they have. Researchers measured lung clearance in 27 participants, including healthy volunteers and PCD patients with different genetic mutations. The goal was to see if certain gene mutations lead to milder disease, which could help doctors tailor future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Albuterol
What this could lead to: If successful, this study could help doctors predict which patients with Primary Ciliary Dyskinesia will have milder or more severe disease, guiding personalized treatment.
What could go wrong: This is a small, early-phase study with only 27 participants, so results may not apply to everyone. It is designed to gather knowledge, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CILIARY DYSKINESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary ciliary dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CILIARY DYSKINESIA

Contacts and locations

Locations

University of North Carolina Chapel Hill

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.